Ying Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ying Chen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ge Yan
Cell Culture Process Development, WuXi Biologics Shanghai China
1 shared publication Guoqi Zhao
Department of Radiation Oncology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai
1 shared publication- Hui Chen
School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia
1 shared publication - Mantian Yin
Department of Oncology, Second Affiliated Hospital of Hainan Medical College, Haikou 570311, China
1 shared publication - Minxiang Li
Department of Nursing, Second Affiliated Hospital of Hainan Medical College, Haikou 570311, China
1 shared publication - Qing Li
Department of Oncology, Second Affiliated Hospital of Hainan Medical College, Haikou 570311, China
1 shared publication
Latest Publications
- Open Access
- 26 July 2021
- Published by Wiley in Scientific Programming
- Vol. 2021, 1-7
IMRT Images Based on Swarm Intelligence Algorithm in the Treatment of Nasopharyngeal Carcinoma and Pain
Objective. To investigate the IMRT treatment of nasopharyngeal carcinoma term effect, toxicity, and technical features. Methods. Sliding windows dynamic CT image-guided IMRT techniques on 31 patients for treatment of nasopharyngeal carcinoma radical radiotherapy, with 30 to 33min irradiation. Target prescription dose GTVnx, GTVnd, CTV1, and CTV2 were 7076Gy, 6870Gy, 6066Gy, and 54Gy, while giving a dose of vital organs, the brain stem, and other restrictions to protect the parotid gland. Results. During 3 to 18 months of follow-up for a median period of 10 months, 1-year locoregional patients progression-free survival, distant metastasis-free survival, and overall survival rates were 93.5, 87.1, and 93.5, respectively. Acute radiation reactions of grade I and II, xerostomia, and radioactive stomatitis were not observed. IMRT DVH analysis showed increased total dose and the irradiation target volume divided doses, reduced OARs illuminated, and the total dose divided doses. Conclusion. Intensity-modulated radiation therapy can achieve good short-term effects, significantly reduce the acute radiation response, and improve the quality of life of patients. It is worthy of promotion and application and in-depth research.
- 26 July 2021
- Published by Wiley in Scientific Programming
- Vol. 2021, 1-7
Open AccessIMRT Images Based on Swarm Intelligence Algorithm in the Treatment of Nasopharyngeal Carcinoma and Pain
Objective. To investigate the IMRT treatment of nasopharyngeal carcinoma term effect, toxicity, and technical features. Methods. Sliding windows dynamic CT image-guided IMRT techniques on 31 patients for treatment of nasopharyngeal carcinoma radical radiotherapy, with 30 to 33min irradiation. Target prescription dose GTVnx, GTVnd, CTV1, and CTV2 were 7076Gy, 6870Gy, 6066Gy, and 54Gy, while giving a dose of vital organs, the brain stem, and other restrictions to protect the parotid gland. Results. During 3 to 18 months of follow-up for a median period of 10 months, 1-year locoregional patients progression-free survival, distant metastasis-free survival, and overall survival rates were 93.5, 87.1, and 93.5, respectively. Acute radiation reactions of grade I and II, xerostomia, and radioactive stomatitis were not observed. IMRT DVH analysis showed increased total dose and the irradiation target volume divided doses, reduced OARs illuminated, and the total dose divided doses. Conclusion. Intensity-modulated radiation therapy can achieve good short-term effects, significantly reduce the acute radiation response, and improve the quality of life of patients. It is worthy of promotion and application and in-depth research.
- Open Access
- 1 July 2018
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 41 (7) , 619-625
Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma
The Intergroup 0116 study has demonstrated a significant survival benefit for completely resected (R0) gastric cancer patients treated with a fluorouracil/leucovorin chemoradiotherapy regimen. However, this regimen is also toxic and less effective in terms of distant disease control. Therefore, a more efficacious and safer regimen is urgently needed. Patients with R0 resected gastric carcinoma received up to two 21-day cycles of postoperative adjuvant preradiation and postradiation DCF chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1 to 3, and a continuous infusion of fluorouracil 750 mg/m2 on days 1 to 5), respectively. Chemoradiotherapy between preradiation and postradiation chemotherapy was initiated on day 43 and consisted of intensity-modulated radiotherapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 5 weeks. A total of 55 patients were evaluated and 76% (42) of patients completed the prescribed therapy. With a median follow-up of 61 months, the 3- and 5-year progression-free survival rates were 67% (95% confidence interval [CI], 54%-80%) and 59% (95% CI, 46%-72%), respectively; and the 3- and 5-year overall survival rates were 72% (95% CI, 60%-84%) and 61% (95% CI, 48%-74%), respectively. The most common grade 3 or greater toxicity, during the chemotherapy phase, was neutropenia (24%). Common grade 3/4 toxicities during concurrent chemoradiotherapy were nausea (32%), vomiting (26%), fatigue (15%), and anorexia (19%). These results demonstrate that this adjuvant regimen is active with an acceptable toxicity profile. A randomized phase 3 trial comparing the Intergroup 0116 chemoradiotherapy regimen with this regimen is underway. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
- 1 July 2018
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 41 (7) , 619-625
Open AccessPhase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma
The Intergroup 0116 study has demonstrated a significant survival benefit for completely resected (R0) gastric cancer patients treated with a fluorouracil/leucovorin chemoradiotherapy regimen. However, this regimen is also toxic and less effective in terms of distant disease control. Therefore, a more efficacious and safer regimen is urgently needed. Patients with R0 resected gastric carcinoma received up to two 21-day cycles of postoperative adjuvant preradiation and postradiation DCF chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1 to 3, and a continuous infusion of fluorouracil 750 mg/m2 on days 1 to 5), respectively. Chemoradiotherapy between preradiation and postradiation chemotherapy was initiated on day 43 and consisted of intensity-modulated radiotherapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 5 weeks. A total of 55 patients were evaluated and 76% (42) of patients completed the prescribed therapy. With a median follow-up of 61 months, the 3- and 5-year progression-free survival rates were 67% (95% confidence interval [CI], 54%-80%) and 59% (95% CI, 46%-72%), respectively; and the 3- and 5-year overall survival rates were 72% (95% CI, 60%-84%) and 61% (95% CI, 48%-74%), respectively. The most common grade 3 or greater toxicity, during the chemotherapy phase, was neutropenia (24%). Common grade 3/4 toxicities during concurrent chemoradiotherapy were nausea (32%), vomiting (26%), fatigue (15%), and anorexia (19%). These results demonstrate that this adjuvant regimen is active with an acceptable toxicity profile. A randomized phase 3 trial comparing the Intergroup 0116 chemoradiotherapy regimen with this regimen is underway. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/